The refractive index for VECTASHIELD Mounting Medium is 1.45.
The VECTASHIELD PLUS Mounting Media are available with or without the counterstain DAPI (4', 6-diamidino-2-phenylindole). The DAPI concentration can be modified by mixing with the corresponding VECTASHIELD PLUS Mounting Medium without DAPI. DAPI produces a blue fluorescence when bound to DNA with excitation at about 360 nm and emission at 460 nm, and is ideal as a nuclear or chromosomal counterstain. Additionally, VECTASHIELD PLUS Mounting Medium does not solidify, but rather, remains a liquid on the slide ‐ which can then be stored without sealing. If desired, coverslips can be sealed around the perimeter using nail polish or plastic sealant. Mounted slides should be stored at 2-8 °C and protected from light.
VECTASHIELD Mounting Medium Antifade Comparison
Other manufacturers measure the antifade properties of their mountants using labeled microspheres or arrayed spots. Vector Labs prefers to measure antifade properties of VECTASHIELD mountants using frozen tissue sections that have been immunohistochemically stained with fluorescently labeled secondary antibodies. Antifade capability is then measured using a 40x objective with real time imaging over 30 seconds of continuous exposure to the excitation illumination. Individual intensity measurements are recorded from 6 separate labeled regions and the average is calculated. The intensity after 30 second exposure is expressed as a percentage of the intensity at zero time. The values for PG are taken from the manufacturer's published results.
VECTASHIELD PLUS with DAPI References:
1. Mahmud, F. et al. (2020) Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer. Cancer Letters (https://www.sciencedirect.com/science/article/abs/pii/S0304383520304663)
2. Schaid, M. et al. (2020) Agonist-independent Gαz activity negatively regulates β-cell compensation in a diet-induced obesity model of type 2 diabetes. Journal of Biological Chemistry (https://www.jbc.org/content/early/2020/11/10/jbc.RA120.015585.short)
3. Gao, Y. et al. (2021) Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells. American Journal of Cancer Research (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840709/)